Shots:
- Origami Therapeutics has entered into a global collaboration & option agreement with Ipsen to develop a small-molecule protein degrader, using Origami’s Oricision platform, for a rare inherited neurodegenerative disorder
- Under the deal, Ipsen will secure an exclusive option to license the program globally after drug candidate nomination &, upon exercise, would take over worldwide development & commercialization
- As per the terms, Origami will receive an upfront payment for the option & research collaboration, development, regulatory & commercial milestone payments, as well as potential royalties
Ref: Businesswire | Image: Origami & Ipsen |Press Release
Related News: Ipsen Receives US FDA Breakthrough Therapy Designation for IPN60340 in Unfit Acute Myeloid Leukemia
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
